NCT03333915: Study of the Safety and Pharmacokinetics of BGB-290 in Subjects With Advanced Solid Tumors

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Germline or somatic BRCA1/2 mutations are only required for the dose expansion phase
Exclusions: Untreated leptomeningeal or brain metastasis

Comments are closed.

Up ↑